Resmed Stock News

Macquarie upgraded shares of ResMed (NYSE:RMD) from a neutral rating to an outperform rating in a research note released on Monday, Price Targets.com reports. A number of other research analysts have also commented on the company. Royal Bank of Canada cut their price target on ResMed from $233.00 to $227.00 and set an underperform rating []

Plus Therapeutics (NASDAQ:PSTV) and ResMed (NYSE:RMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations. Volatility & Risk Plus Therapeutics has a beta of 0.35, indicating that its stock price is 65% […]

Chevy Chase Trust Holdings Inc. cut its holdings in ResMed Inc. (NYSE:RMD) by 3.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,383 shares of the medical equipment providers stock after selling 3,380 shares during the quarter. Chevy Chase Trust Holdings []

Brokerages predict that ResMed Inc. (NYSE:RMD) will report earnings of $1.48 per share for the current quarter, Zacks reports. Four analysts have made estimates for ResMeds earnings. The lowest EPS estimate is $1.42 and the highest is $1.52. ResMed reported earnings per share of $1.41 during the same quarter last year, which suggests a positive [] The post Analysts Anticipate ResMed Inc. (NYSE:RMD) to Post $1.48 EPS appeared first on ETF Daily News .

This is an evaluation of likely coming stock prices, not an appraisal of RMD's product line or management's competitive abilities. They're already evaluated by big-$ investment analysts and portfolio

Patient monitoring devices in this report refer to the sensors which are used in smart wearable devices. The patient monitoring devices market is driven by increasing demand for wearable for infants and continuously evolving sensor technology. With increasing personal care

The global CPAP Ventilators market was valued at 2544.78 Million USD in 2020 and will grow with a CAGR of 4.23% from 2021 to 2027. A CPAP ventilator can help patients transition from intubation breathing tubes to self-breathing, as well

According to the new market research report "Respiratory Care Devices Market by Product (Therapeutic (Ventilator, Mask, PAP Device, Inhaler, Nebulizer), Monitoring (Pulse Oximeter, Capnograph), Diagnostic, Consumables), End User (Hospital, Home Care), COVID-19 Impact - Global Forecast to 2026", published by

ResMed Inc. (NYSE:RMD) insider James Hollingshead sold 2,400 shares of the companys stock in a transaction on Wednesday, December 1st. The stock was sold at an average price of $256.84, for a total transaction of $616,416.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC []

Legacy Wealth Asset Management LLC reduced its position in shares of ResMed Inc. (NYSE:RMD) by 7.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,987 shares of the medical equipment providers stock after selling 393 shares during the period. ResMed accounts for []

NuWave Investment Management LLC bought a new stake in ResMed Inc. (NYSE:RMD) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,112 shares of the medical equipment providers stock, valued at approximately $293,000. Several other hedge funds have also recently []

Tandem Investment Advisors Inc. grew its stake in shares of ResMed Inc. (NYSE:RMD) by 6.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 111,223 shares of the medical equipment providers stock after buying an additional 7,058 shares during the period. ResMed []

Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.

Wall Street analysts predict that ResMed Inc. (NYSE:RMD) will post sales of $922.63 million for the current fiscal quarter, Zacks reports. Four analysts have made estimates for ResMeds earnings, with the lowest sales estimate coming in at $915.60 million and the highest estimate coming in at $935.00 million. ResMed reported sales of $800.01 million in []